Neuberger Berman Group LLC Grows Stock Position in Pfizer Inc. $PFE

Neuberger Berman Group LLC lifted its stake in Pfizer Inc. (NYSE:PFE) by 203.8% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 9,012,811 shares of the biopharmaceutical company’s stock after buying an additional 6,045,763 shares during the quarter. Neuberger Berman Group LLC owned approximately 0.16% of Pfizer worth $229,346,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Grey Fox Wealth Advisors LLC purchased a new position in Pfizer during the third quarter valued at approximately $29,000. Howard Hughes Medical Institute purchased a new stake in Pfizer in the 2nd quarter worth approximately $30,000. Darwin Wealth Management LLC acquired a new stake in shares of Pfizer during the 2nd quarter worth approximately $32,000. Evelyn Partners Asset Management Ltd acquired a new stake in shares of Pfizer during the 2nd quarter worth approximately $33,000. Finally, True Wealth Design LLC increased its holdings in shares of Pfizer by 302.5% during the 3rd quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 974 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Price Performance

NYSE:PFE opened at $27.07 on Friday. Pfizer Inc. has a one year low of $20.92 and a one year high of $27.94. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.87 and a current ratio of 1.16. The stock has a market cap of $153.93 billion, a PE ratio of 19.90 and a beta of 0.47. The stock has a 50 day moving average price of $26.30 and a 200 day moving average price of $25.47.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, topping analysts’ consensus estimates of $0.57 by $0.09. The company had revenue of $17.56 billion for the quarter, compared to analyst estimates of $16.93 billion. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The firm’s revenue for the quarter was down 1.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.63 earnings per share. Equities research analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, March 6th. Investors of record on Friday, January 23rd were issued a $0.43 dividend. The ex-dividend date of this dividend was Friday, January 23rd. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.4%. Pfizer’s dividend payout ratio is currently 126.47%.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: China approved Pfizer’s GLP‑1 weight‑management drug (Xianweiying / ecnoglutide), opening a large new market for its obesity franchise and reinforcing Pfizer’s push into metabolic drugs — this expands addressable market and supports long‑term revenue potential. China approves Pfizer GLP-1 drug for weight management
• Positive Sentiment: Analyst upgrade: Argus Research upgraded PFE to Buy and set a $35 target, citing progress in the GLP‑1 program and oncology pipeline — this can attract buy interest and boost sentiment among dividend and income investors. Argus Turns Bullish on Pfizer
• Positive Sentiment: Oncology wins: positive Phase 3 EV‑304 PADCEV results and FDA full approval for BRAFTOVI combinations were highlighted as re‑framing Pfizer’s long‑term growth prospects in oncology — supports diversification away from COVID revenues. Pfizer Obesity Nod In China And Cancer Wins
• Positive Sentiment: Pipeline expansion in China: Pfizer launched a Phase 1 heart‑failure candidate study in China, signaling continued local R&D investment that could yield future launches in a large market. Pfizer Adds New Early-Stage Heart Failure Candidate
• Neutral Sentiment: Investor attention & valuation debate: multiple articles note heightened retail/institutional interest and divergent valuation views (trending stock coverage, DCF vs. long‑term return debates) — increases volatility/volume but not a direct fundamental change. Pfizer Is a Trending Stock
• Neutral Sentiment: Competition & generics risk for GLP‑1s: coverage notes Pfizer will face crowded competition (and price pressure risk) even as it gains approvals — a mixed commercial outlook. Weight-Loss Drug Approved in China — Up Against Generic Rivals
• Negative Sentiment: Structural headwinds remain: analysts reiterate risks from declining COVID revenues, upcoming patent expirations and U.S. drug‑pricing pressures (IRA) that could limit near‑term growth despite new launches. Can Pfizer Reignite Growth?
• Negative Sentiment: Policy/legal noise: a recent court ruling awarded Pfizer $29M in an SEC settlement dispute (one‑time benefit), but legal and policy developments remain sources of uncertainty for investors. Judge approves Pfizer, SEC settlement

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the stock. Royal Bank Of Canada started coverage on shares of Pfizer in a research note on Tuesday, February 24th. They issued an “underperform” rating and a $25.00 target price for the company. HSBC reaffirmed a “buy” rating and issued a $29.00 price objective on shares of Pfizer in a report on Wednesday, December 10th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $27.00 price objective on shares of Pfizer in a research report on Wednesday, February 4th. Guggenheim reissued a “buy” rating on shares of Pfizer in a research note on Wednesday, December 17th. Finally, Daiwa Securities Group cut Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 target price on the stock. in a research report on Thursday, February 12th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, fourteen have issued a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $28.05.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.